TG Therapeutics’ (TGTX) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report released on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has a $25.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on TGTX. StockNews.com lowered TG Therapeutics from a buy rating to a hold rating in a research note on Saturday, February 24th. B. Riley increased their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a buy rating in a report on Monday, February 5th. HC Wainwright restated a buy rating and issued a $45.00 target price on shares of TG Therapeutics in a report on Thursday. Finally, The Goldman Sachs Group increased their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $29.00.

TG Therapeutics Stock Performance

TGTX opened at $13.99 on Thursday. The firm has a market cap of $2.16 billion, a PE ratio of 699.85 and a beta of 2.30. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $15.13 and a 200-day simple moving average of $13.87. TG Therapeutics has a fifty-two week low of $6.46 and a fifty-two week high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. The business had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. During the same period last year, the company posted ($0.39) EPS. As a group, equities analysts predict that TG Therapeutics will post -0.12 EPS for the current fiscal year.

Insider Activity

In related news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of TG Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TGTX. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $27,000. PNC Financial Services Group Inc. raised its holdings in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,014 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of TG Therapeutics by 102.3% during the second quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 5,152 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new stake in shares of TG Therapeutics during the second quarter worth $46,000. Finally, KBC Group NV acquired a new position in TG Therapeutics during the fourth quarter worth $54,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.